Aging is the biggest risk-factor for cancers, heart disease, Alzheimer’s, and other detrimental indications. We’re on a mission to therapeutically reverse aging to prevent and treat these diseases.
We tackle the complexity of aging with deep-learning-guided, multiomics drug design that optimizes thousands of drug interactions implicated in longevity, safety, and systemic deliverability.
Our drug discovery and design platform, CANDO, is a robust IP-generating engine benchmarked and validated in hundreds of applications across dozens of indications. With Mansarover, we're excited to utilize its multiomics scale to design new rejuvenating therapies for longevity and age-related diseases. Read a few selected publications on our platform here:
Entrepreneurial lead and primary platform/ML developer. 5+ years experience in fullstack development. 2+ year research fellow at the Division of Bioinformatics, University at Buffalo. Currently studying Regenerative Biology and Physics at Harvard University; student member at Harvard Innovation Labs.
Primary platform developer leading network/omics integration. Received PhD in Biomedical Informatics from the University at Buffalo. 6+ years of research in computational drug discovery.
Professor and Division Chief of Bioinformatics at the University at Buffalo. Led 20+ year research program in structural biology and computational drug discovery with multiple therapeutics patents. Received PhD from the University of Maryland followed by a Postdoctoral Fellowship at Stanford University.
As a drug discovery company, we're always looking for new and exciting partnership opportunities with companies in longevity biotech. Don't hesitate to reach out if your company is working on complex mechanisms of aging, multiple difficult targets, or transcription factors/biologics therapies in need of improved deliverability.
Partnering: partnering@mansarover.us
Inquires: brennan@mansarover.us
@ Harvard Innovation Labs
Batten Hall, 125 Western Ave
Allston, MA 02134